The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.
Valeant Reports Loss and Cuts Forecast in Preliminary Financial Statement
ByKATIE THOMAS
Mar 15, 2016